Standard Biotools (LAB) EBIAT (2016 - 2025)
Standard Biotools (LAB) has disclosed EBIAT for 16 consecutive years, with -$13.2 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT rose 39.62% to -$13.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$111.8 million, a 6.48% increase, with the full-year FY2024 number at -$138.9 million, down 86.03% from a year prior.
- EBIAT was -$13.2 million for Q3 2025 at Standard Biotools, up from -$33.5 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$9.4 million in Q4 2021 to a low of -$76.3 million in Q1 2022.
- A 5-year average of -$28.2 million and a median of -$21.0 million in 2023 define the central range for EBIAT.
- Peak YoY movement for EBIAT: crashed 305.33% in 2022, then surged 77.92% in 2023.
- Standard Biotools' EBIAT stood at -$9.4 million in 2021, then plummeted by 121.07% to -$20.8 million in 2022, then increased by 5.13% to -$19.8 million in 2023, then tumbled by 97.67% to -$39.1 million in 2024, then skyrocketed by 66.14% to -$13.2 million in 2025.
- Per Business Quant, the three most recent readings for LAB's EBIAT are -$13.2 million (Q3 2025), -$33.5 million (Q2 2025), and -$26.0 million (Q1 2025).